Malin Lindstedt, founder of SenzaGen and GARD, is awarded the NYTÄNKAREN 2017 (INNOVATIVE THINKER 2017) prize by the Swedish foundation Research Without Animal Experiments

SenzaGen’s co-founder, Professor Malin Lindstedt, has been awarded the Nytänkaren 2017 (Innovative Thinker 2017) Prize and SEK 400,000 by the Swedish fundation for Research Without Animal Experiments for her work on the development of animal-free testing methods. The prize was awarded today, 16 October at a ceremony at Research Without Animal Experiments offices in Stockholm.

Professor Malin Lindstedt receives the prize for her successful development of advanced testing methods that can reduce and replace the use of animals in the risk assessment of chemicals and consumer products. Malin Lindstedt works at Lund University’s Department of Immunotechnology, where she has directed the research that lies behind the series of allergy tests based on cell-based gene analysis that are now marketed under the name GARD. Under her direction, a research team started by developing a test for skin allergies. They then went on to develop a test to determine which substances can cause respiratory allergies, and most recently a test that can analyze proteins associated with food allergies.

While working on the development of the technology behind GARD, Malin Lindstedt founded SenzaGen, the company which is now responsible for making this technology available on the global market. The first test to be developed, GARDskin, is already seeing limited use. GARDskin is at the present time undergoing a validation process for inclusion in the OECD Chemical Test Guidelines, which would result in the method achieving its international breakthrough as an eligible method that meets regulatory requirements for the risk assessment of chemicals.

The prize from Research Without Animal Experiments highlights the practicability of using advanced methods to continue to reduce and replace the use of animals in the risk assessment of chemicals and consumer products both inside and outside Sweden. With the NYTÄNKAREN prize and its associated funding, Research Without Animal Experiments wishes particularly to support the research team’s ambitions to continue their development of allergy tests.

 

News about the prize can be viewed on the Research Without Animal  Experiments website:

http://forskautandjurforsok.se/knappar-pa-startsidan/nytankaren-2017/

 

For more information

Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

Grundaren av SenzaGen och GARD, Malin Lindstedt, tilldelas priset som NYTÄNKAREN 2017 av stiftelsen Forska Utan Djurförsök

SenzaGens medgrundare, Professor Malin Lindstedt har tilldelats utmärkelsen Nytänkaren 2017 och 400 000 kronor av stiftelsen Forska Utan Djurförsök för sitt arbete med utveckling av djurfria testmetoder. Idag delades priset ut vid en sammankomst hos stiftelsen Forska Utan Djurförsök Stockholm

Professor Malin Lindstedt får priset för sin framgångsrika utveckling av avancerade testmetoder som kan minska och ersätta användningen av djur vid riskbedömning av kemikalier och konsumentprodukter.  Malin Lindstedt arbetar på Institutionen för Immunteknologi, Lunds universitet, där hon lett forskningen som ligger bakom den serie allergitester som nu marknadsförs under namnet GARD och som utgår från cellbaserade genanalyser. Under hennes ledning började en forskargrupp med att utveckla ett test för hudallergier. De har sedan fortsatt utvecklingen med ett test för att avgöra vilka ämnen som kan orsaka luftvägsallergier, och nu senast ett test som kan analysera proteiner som är förknippade med matallergier.

Under sitt arbete med att utveckla teknologin bakom GARD grundade Malin Lindstedt företaget SenzaGen, som nu ansvarar för att göra teknologin tillgänglig på den globala marknaden. Det först utvecklade testet, GARDskin, har redan börjat användas i begränsad omfattning. GARDskin ingår i en valideringsprocess för att upptas i OECD:s testriktlinjer för kemikalier, vilket skulle leda till att metoden får internationellt genomslag som valbar metod för att uppfylla regulatoriska krav för riskbedömning av kemikalier.

Priset från Forska utan Djurförsök belyser möjligheten att med avancerade metoder fortsätta att minska och ersätta användning av djur vid riskbedömning av kemikalier och konsumentprodukter i och utanför Sverige. Forska Utan Djurförsök vill med NYTÄNKAREN och tillhörande anslag särskilt stödja forskargruppens ambitioner att fortsätta utvecklingen av allergitester.

Nyheten om priset hos Stiftelsen Forska Utand Djurförsök
http://forskautandjurforsok.se/knappar-pa-startsidan/nytankaren-2017/

 

För mer information:
Anki Malmborg Hager, vd, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telefon: 0768 284822

 

 

New colleague at SenzaGen

Welcome to SenzaGen Henrik Appelgren!

Henrik has started his position as Chief Scientific Officer with us here at SenzaGen this week. Henrik is a biologist with a PhD in genetic toxicology. He has been working at the Swedish Chemicals Agency for 15 years, where he worked as Sweden’s national coordinator in the OECD Test Guideline Programme. Henrik has a deep knowledge in alternative test methods and of regulatory work in the chemical industry – both nationally and internationally. He also has long experience of health risk assessments of chemicals in all European legislation. He is, and has been, a member of several scientific expert councils including FORMAS, the Swedish Research Council, the Swedish Fund for Research Without Animal Experiments, the Scandinavian Society for Cell Toxicology and EUToxRisk.

Henrik strengthens SenzaGen’s management for the commercialization of the GARD tests and prior to the company’s planned listing on Nasdaq First North.

We are very happy to have you in our team, Henrik!

SenzaGen is presenting at hosted session at the EUROTOX Congress in Bratislava

SenzaGen new Chief Scientific officer Hernik Appelgren will give a presentation on 21st century testing for skin sensitisation and updates on application of the GARD platform at The 53rd  European Congress of the European Societies of Toxicology, EUROTOX, on the 12th of Sept. SenzaGen is also Exhibiting at the congress and presenting two posters

The meeting promises scientific sessions houndreds of abstract presentations, exhibitors meetings, continuing education courses, awards presentations, receptions,  and  an exhibition area for exhibitors offering you the latest information on services and technology
Presentation details
Tuesday 12 Sep 10-11 AM | 
Memories, Hotel Sheraton
21st Century Sensitisation testing: Can one test be stand alone? Regulatory challenges and GARD applications update
.

Presented by: Henrik Appelgren, Chief Scientific Officer and regulatory expert at SenzaGen

Allergy is a growing health problem in humans. The data requirements for the assessment of sensitisation in chemical legislations have been based on animal assays, which until now have served as the golden standard. However, in vitro assays have been developed which need to be combined in order to address all key events for sensitisation to fulfil the demands in e. g., Reach. However, The Genomic Allergen Rapid Detection Skin (GARDskin) assay addresses all the key regulatory questions regarding sensitisation, including potency – How? This session we will give an update on the validation status and the different applications of GARD.

Posters
ID 668 | Session 2 | Board no P-04-02-07 | Monday, Sept 11 from 15:00
Transferability of the GARDskin assay to two independent laboratories.

ID 438 | Session 4 | Board number P-09-02-31 | Tuesday, Sept 12 from 15:00
The GARD platform for potency assessment of skin sensitizing chemicals

New colleague at SenzaGen

Welcome to SenzaGen Anna Chérouvrier Hansson!

Anna has started her position as Chief Commercial Officer with us here at SenzaGen this week. Anna comes from Camurus, a pharmaceutical company developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions. At Camurus, Anna was Director of Marketing and responsible for the Medical Device Business Unit. She has previously worked as Head of Business Development Life Science at Invest in Skåne, Partner at Zitha Consulting and in a number of senior positions in European pharmaceutical and chemical companies. Anna was born in France, studied and worked in Germany and Luxembourg before moving to Sweden in 2000 to study a Master in Business Administration and Business Law and decided to stay. Anna strengthens SenzaGen’s management for the commercialization of the GARD tests and prior to the company’s planned listing on Nasdaq First North.

We are very happy to have you in our team, Anna!

senzagen skin derma

Meet us in Almedalen – The researchers behind the GARDtest and SenzaGen’s lab technicians on site.

Meet Andy Forreryd from Lund University and Angelica Johansson from SenzaGen in the organisation of Research Without Animal Experiments, 6th and 7th of July. During two seminars, Andy will tell us about the research behind GARD. There will be opportunities for questions and hands on practical lab work so that you can experience and see how the test works.

With research money from different organisations, including Research Without Animal Experiments, the university has developed a unique allergy test that with higher precision than existing tests can determine if a chemical can induce skin allergy. The test is carried out in test tubes and replaces the need for animal testing when safety testing chemicals.

The GARDtestet is now owned, sold and marketed by SenzaGen AB for global commercialization with the aim of becoming a new industry standard on the international chemical safety testing market. Angelica Johansson is on site to talk about GARD’s journey from laboratory to global market. Link in Swedish.

senzagen gard session

SenzaGen is presenting at hosted sessions at Society of Toxicology 56th Annual Meeting in Baltimore March 12-16, 2017

Lund University Scientist Andy Forreryd and SenzaGen CEO Anki Malmborg Hager will give a presentatios about the GARD assay at exhibitor hosted sessions at the Society of Toxicology 56th Annual Meeting in Baltimore, on the 13th and 14th of March.

The meeting promises more than 150 scientific sessions, approximately 350 ToxExpo exhibitors offering you the latest information on services and technology, thousands of abstract presentations, continuing education courses, awards presentations, receptions, career guidance and support, and more.

Presentations details

– Replacement of Animal Testing for CLP/GHS Classification of Skin Sensitizers is now possible using a Modified Genomic GARDskin [OECD TGP 4.106] Assay
SenzaGen presents the latest development towards reliable potency classification of chemicals according to CLP 1A and 1B, taking both LLNA and Human potency data in consideration. The assay is based on GARDskin and utilizes a refined gene expression signature developed specifically for potency categorization with high predictability.

Date: 3/13 Time: 13:30 -14:30  Room: 338

– Advantages with Genome Testing Opening up the Landscape for New Application Possibilities for Sensitization Testing using SenzaGen’s Genomic GARD Assay
SenzaGen’s GARD assay is based on expression analysis of predictive genomic biomarker signatures. Prediction calls of test substances are generated by computational methods based on machine learning. SenzaGen presents their experience in skin and respiratory sensitization testing, working with challenging compounds and mixtures, active substances, potency classification and NOEL interpretation.

Date: 3/14 Time: 13:30-14:30  Room: 338

These session are Exhibitor-Hosted Session. Although not an official part of the SOT Annual Meeting scientific program, its presentation is permitted by the Society.

Attendees are welcomed from researcher community, industry, manufacturers, regulatory agencies, consultants, CROs and every one interested in safety testing of chemical compounds.

ceo senzagen anki malmborg hager

Anki Malmborg Hager elected one of the two most powerful people among Lund technology companies according to Rapidus ranking

The news site Rapidus has been looking into nealy 180 companies of extended IDEON business park in Lund, Sweden in a unique survey of decision-makers of the region. Ericsson veteran Tord Wingren and Alligator Bioscience co-founder Anki Malmborg-Hager were ranked two of the most powerful people among Lund technology companies.

Rapidus writes:

Leeding up to the expansion of the concept of Ideon, Rapidus went through the records of company boards and chief executives of all technology companies which have their registered office at Ideon Medicon Village, Mobile Heights Center and Edison Park.

In total it ads up to around 700 decision makers of almost 180 companies. Most of them only sit on one board or CEO positions however 56 of these people have posiotions in more than one technology company on the extended Ideon area. At the top of the list are a dozen people with at least three appointments, including the CEO of Jolife Erik von Schenck and Professor Carl Borrebaeck, who among several appointments is on the board of Alligator Bioscience and Clinical Laserthermia Systems.

Read the full news at Rapidus site (only subscribers)

blue senzagen logo

SenzaGen starts blogging for Swedish leading financial newspaper Dagens Industri.

Follow our CEO, Anki Malmborg Hager here on the new blog at our web site under Mixed Media/blogs or at Di Gasell.

The blog will be in Swedish

SenzaGen nominated for Guldråttan -the Golden Rat

SenzaGen has been nominated for the honorable price “Guldråttan” -the Golden Rat, a prize awarded by Djurens Rätt (the Animal Rights) to companies that make exceptional contribution to animal wellfare.

SenzaGen is able to greatly reduce animal use with their animal free allergy tests for cosmetic ingredients, raw material production and the pharmaceutical industries. With the company’s test GARD, which is performed in vitro, the number of animals used for testing in these industries can be heavily reduced and now that SenzaGen is expanding globally, the impact can be even greater.

“Guldråttan is Sweden’s finest animal rights prize and awarded since 1987 by Djurens Rätt to a person or persons who have made an exceptional contribution during the year to animal well fare” Djurens Rätt says ontheir site.

It is now possible to vote on who should be awarded Guldråttan 2016. Voting will run until April 10 and the winner will be presented at Djurens Rätts National Conference in Stockholm on 14-15 May.

Participate and vote at http://www.djurensratt.se/guldrattan2016 (in Swedish) Link no longer available